CCDR: Volume 41S-5, November 19, 2015: Antimicrobial resistance and innovation

In this supplement: Antimicrobial resistance and innovation

In this issue, read about how normal flora can now be manufactured to treat Clostridium difficile and potentially other conditions, learn how optimal vaccine use can minimize the need for antibiotics, and see how the Canadian Institutes of Health Research has been funding research on antimicrobial resistance (AMR) innovation. In the ID News section read about the use of nanotechnologies to treat HIV, tuberculosis and yeast infections, and learn about a new protein inhibitor to treat malaria. This is the last in a series of theme issues to highlight the three pillars of Canada's Federal Action Plan on AMR: Surveillance, Stewardship and Innovation. If we all continue to work together on this three-pillar approach, the potentially devastating effects of AMR can be averted.

Table of contents

Innovation
Using bugs as drugs: Microbial ecosystem therapeutics
Allen-Vercoe E, Petrof EO

Commentary
Immunization as a tool to combat antimicrobial resistance
Spika J, Rud EW

Overview
The Canadian Institutes of Health Research response to antimicrobial resistance
Pagé EL, Desnoyers S, Létourneau IJ, Keown K, Jackson A, Ouellette M

ID News
Innovation and antimicrobial resistance

Upcoming conferences
March 9-12, 2016: European Society of Clinical Microbiology and Infectious Diseases (ESCMID). International Meeting on Microbial Epidemiological Markers. Navigating Microbial Genomes: Insights from the Next Generation. Estoril, Portugal.

March 30-April 2, 2016: Association of Medical Microbiology and Infectious Disease Canada - AMMI Annual Conference. Vancouver, British Columbia.

Search CCDR